What are Vir Biotechnology, Inc.'s total assets?

Vir Biotechnology, Inc. (VIR) holds $1.0B in total assets, down 21.6% year over year.

How much debt does Vir Biotechnology, Inc. have?

Vir Biotechnology, Inc. carries $95.6M in total debt against $812.8M of shareholders' equity, a debt-to-equity ratio of 0.12.

How much cash does Vir Biotechnology, Inc. have?

Vir Biotechnology, Inc. holds $283.0M in cash and equivalents.

Can Vir Biotechnology, Inc. cover its short-term obligations?

Its current ratio is 7.11 — current assets exceed current liabilities.

Where does Vir Biotechnology, Inc.'s balance sheet data come from?

Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Vir Biotechnology, Inc. VIR Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$241.07M-24.4%	$318.7M+22.0%	$261.29M-69.9%	$867.97M+139%
Short-term investments	$228.75M-66.3%	$678.05M-46.7%	$1.27B-16.5%	$1.52B+601%
Restricted cash	$1.92M-97.8%	$89.39M+574%	$13.27M+4.6%	$12.68M+47.6%
Prepaid expenses and other current assets	$165.96M-8.6%	$181.54M-38.5%	$295.32M-1.8%	$300.86M+92.3%
Total current assets	$514.08M-50.7%	$1.04B-34.4%	$1.59B-37.0%	$2.52B+61.2%
Property and equipment, net	$55.62M-12.0%	$63.18M-34.2%	$96.02M-9.1%	$105.61M+147%
Accumulated depreciation	$47.16M+28.2%	$36.79M+8.5%	$33.9M+63.4%	$20.74M—
Operating lease right-of-use assets	$62.1M+4.1%	$59.68M-16.2%	$71.18M-13.8%	$82.56M-5.3%
Goodwill	$16.94M0.0%	$16.94M0.0%	$16.94M0.0%	$16.94M0.0%
Intangible assets, net	$7.85M-3.3%	$8.12M-64.0%	$22.57M-31.1%	$32.76M-1.6%
Other non-current assets	$24.7M+105%	$12.06M-2.8%	$12.41M-14.8%	$14.57M+425%
Equity method investments	$314.58M+65.6%	$190.02M+80.5%	$105.28M+340%	$23.93M-88.1%
Equity securities	$6.08M+39.7%	$4.35M-55.9%	$9.85M—	——
Total assets	$1B-28.3%	$1.4B-27.1%	$1.92B-31.5%	$2.8B+43.4%
Accounts payable	$32.61M+36.5%	$23.89M-30.7%	$34.47M+12.2%	$30.72M+20.6%
Accrued expenses	$83.01M-15.7%	$98.52M-5.5%	$104.22M-78.7%	$489.09M+107%
Operating lease liabilities, current	$8.8M+13.5%	$7.75M-39.8%	$12.87M+211%	$4.14M+5.3%
Accrued interest	$3.6M-28.0%	$5M+25.0%	$4M—	——
Total current liabilities	$92.82M-22.4%	$119.66M-31.8%	$175.41M-65.7%	$511.03M+49.8%
Operating lease liabilities, non-current	$89.05M-1.2%	$90.14M-19.3%	$111.67M-9.8%	$123.84M-7.3%
Other non-current liabilities	$21.58M+48.0%	$14.58M-7.6%	$15.78M+42.0%	$11.12M+338%
Total liabilities	$237.55M-4.4%	$248.43M-24.4%	$328.82M-54.6%	$724.13M+38.6%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	300M+2,142,757%	14K+7.7%	13K0.0%	13K0.0%
Additional paid-in capital	$1.97B+2.8%	$1.91B+4.5%	$1.83B+7.0%	$1.71B+8.8%
Retained earnings	-$1.2B-57.6%	-$759.78M-219%	-$237.82M-163%	$377.24M+372%
Accumulated other comprehensive income (loss)	-$2.06M-19.8%	-$1.72M-111%	-$815K+91.1%	-$9.12M-730%
Total stockholders' equity	$765.28M-33.5%	$1.15B-27.7%	$1.59B-23.5%	$2.08B+45.1%
Total liabilities and stockholders' equity	$1B-28.3%	$1.4B-27.1%	$1.92B-31.5%	$2.8B+43.4%
Short- term Investments	$228.75M-66.3%	$678.05M-46.7%	$1.27B-16.5%	$1.52B+601%
Net Investment in Lease	$62.1M+4.1%	$59.68M-16.2%	$71.18M-13.8%	$82.56M-5.3%
Other intangible assets—net	$7.85M-3.3%	$8.12M-64.0%	$22.57M-31.1%	$32.76M-1.6%
Investments	$314.58M+65.6%	$190.02M+80.5%	$105.28M+340%	$23.93M-88.1%
Operating lease right-of-use assets	$62.1M+4.1%	$59.68M-16.2%	$71.18M-13.8%	$82.56M-5.3%
Other Assets	$24.7M+105%	$12.06M-2.8%	$12.41M-14.8%	$14.57M+425%
Property, plant and equipment at cost	$102.78M+2.8%	$99.97M-23.1%	$129.91M+2.8%	$126.35M—
Operating Lease Right-of-Use Assets in Other Assets	$62.1M+4.1%	$59.68M-16.2%	$71.18M-13.8%	$82.56M-5.3%
Professional Service Fees Payable	$3.33M+46.7%	$2.27M-33.6%	$3.42M-14.3%	$3.99M—
Contingent Consideration Liability (Non-Current)	$34.1M+41.8%	$24.05M-7.4%	$25.96M+4.1%	$24.94M+9.3%
Accrued expenses and other liabilities	$83.01M-15.7%	$98.52M-5.5%	$104.22M-78.7%	$489.09M+107%
Total debt	$97.85M0.0%	$97.89M-21.4%	$124.54M-2.7%	$127.97M-6.9%
Unrecognized Tax Benefits	$17.3M-3.4%	$17.9M+31.6%	$13.6M+28.3%	$10.6M—
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—
Common Stock Shares Issued	139.5M+1.8%	137M+1.6%	134.8M+1.2%	133.2M—
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M—
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$14K0.0%	$14K+7.7%	$13K0.0%	$13K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—
Unrealized Gains on Investments	$1.12M-24.5%	$1.49M+42.5%	$1.04M—	——
Unrealized Losses on Investments (Before Tax)	$20K-71.8%	$71K-45.4%	$130K—	——
Cumulative Cost Basis	$102.78M+2.8%	$99.97M-23.1%	$129.91M+2.8%	$126.35M—
Payroll and related expenses	$28.72M-7.8%	$31.17M—	——	——
Professional service fees	$3.33M+46.7%	$2.27M-33.6%	$3.42M-14.3%	$3.99M—
Research and development expenses	$35.3M+20.8%	$29.23M—	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$20K-71.8%	$71K-45.4%	$130K—	——
Gross Unrealized Gains	$1.12M-24.5%	$1.49M+42.5%	$1.04M—	——
Total cash, cash equivalents and investments	$781.59M-28.6%	$1.1B—	——	——
Plus: Cash deposits	$98.96M+204%	$32.52M—	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$0—
Common stock, shares authorized (in shares)	$300M0.0%	$300M0.0%	$300M0.0%	$300M—
Common stock, shares issued (in shares)	$139.47M+1.8%	$136.96M+1.6%	$134.78M+1.2%	$133.24M—
Common Stock, Shares, Outstanding	$139.47M+1.8%	$136.96M+1.6%	$134.78M+1.2%	$133.24M—
Excess funds payable under grant agreements	$1.83M-84.3%	$11.59M+25.9%	$9.2M+20.3%	$7.65M—
Financial Assets Amortized Cost Basis	$683.36M-36.6%	$1.08B-33.6%	$1.62B-32.5%	$2.4B—
Other accrued liabilities	$5.04M+30.1%	$3.87M-9.5%	$4.28M-66.3%	$12.71M—
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$0—
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M—
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Unrecognized tax benefits	$17.3M-3.4%	$17.9M+31.6%	$13.6M+28.3%	$10.6M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Vir Biotechnology, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Vir Biotechnology, Inc.'s total assets?: Vir Biotechnology, Inc. (VIR) holds $1.0B in total assets, down 21.6% year over year.
How much debt does Vir Biotechnology, Inc. have?: Vir Biotechnology, Inc. carries $95.6M in total debt against $812.8M of shareholders' equity, a debt-to-equity ratio of 0.12.
How much cash does Vir Biotechnology, Inc. have?: Vir Biotechnology, Inc. holds $283.0M in cash and equivalents.
Can Vir Biotechnology, Inc. cover its short-term obligations?: Its current ratio is 7.11 — current assets exceed current liabilities.
Where does Vir Biotechnology, Inc.'s balance sheet data come from?: Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.